Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
about
Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.Study protocol of the RAND-study: a multicenter, prospective cohort study investigating response and adherence to nilotinib treatment in chronic myeloid leukemia.A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia.Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision AnalysisEstimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis.Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.Estimation of the prevalence and direct medical costs of chronic myeloid leukemia in the I.R. of Iran in the era of tyrosine kinase inhibitors.Complex variant of Philadelphia translocation involving chromosomes 9, 12, and 22 in a case with chronic myeloid leukaemiaThe BCL2L11 deletion polymorphism is not associated with imatinib resistance in chronic myeloid leukemia patients: meta-analysis.Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials.Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy.Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients.Impact of CYP3A4*18 and CYP3A5*3 Polymorphisms on Imatinib Mesylate Response Among Chronic Myeloid Leukemia Patients in Malaysia.Reconsideration of BCR-ABL protein flow cytometric immunobead assay: how potent to diagnose and monitor chronic myeloid leukemia?The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study
P2860
Q33756387-C023404E-B8E4-4C23-BF0B-75852C31DF0FQ34272962-D66BD1D0-6292-4718-8AAE-4E324F325459Q35142510-053ECEE5-0BD7-41BF-9643-C67C95E27037Q36302377-A969BCA3-791C-4313-B348-785D461AC7F7Q36400944-2D2B033B-98D5-4BF8-8C15-3F824D44D1A1Q37598156-685564FC-5D09-4962-9877-3F5EFAA7A2E9Q38178192-FA0415E2-8C1B-4DDE-9F36-AE13F595D342Q39116591-7E63A074-1633-41B0-ABE1-E2F008B3F836Q39350678-7E661BBF-8916-442A-B2F8-89FE8C0F5020Q39909602-E307D5F2-FEBA-4507-8BCF-6CB5D13B9B6BQ41861025-7BA5B3FF-E6E0-4365-8248-C196B80C715FQ47162677-D1ABE630-8E5F-4AE1-8F36-0B30F2D35F81Q48319994-9186A7A8-CE17-4CE4-8E24-E30B100F8F2CQ49888044-5A6C7473-113F-4971-97A0-5661E34F8A4CQ50916805-25D0EC12-EE1B-4014-BF7C-6BE3334E26A5Q53803475-2060970F-C291-4169-A201-EB45685ED069Q54266782-DC7C27F0-2117-4B1E-9319-53C0659CFDD1Q58605235-53A0501C-0E81-49A6-AABE-65E089E0B476
P2860
Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Chronic myeloid leukemia: ESMO ...... osis, treatment and follow-up.
@ast
Chronic myeloid leukemia: ESMO ...... osis, treatment and follow-up.
@en
Chronic myeloid leukemia: ESMO ...... osis, treatment and follow-up.
@nl
type
label
Chronic myeloid leukemia: ESMO ...... osis, treatment and follow-up.
@ast
Chronic myeloid leukemia: ESMO ...... osis, treatment and follow-up.
@en
Chronic myeloid leukemia: ESMO ...... osis, treatment and follow-up.
@nl
prefLabel
Chronic myeloid leukemia: ESMO ...... osis, treatment and follow-up.
@ast
Chronic myeloid leukemia: ESMO ...... osis, treatment and follow-up.
@en
Chronic myeloid leukemia: ESMO ...... osis, treatment and follow-up.
@nl
P2093
P2860
P356
P1433
P1476
Chronic myeloid leukemia: ESMO ...... nosis, treatment and follow-up
@en
P2093
ESMO Guidelines Working Group
J-L Steegmann
M Baccarani
M Dreyling
P2860
P304
P356
10.1093/ANNONC/MDS228
P478
23 Suppl 7
P577
2012-10-01T00:00:00Z